Drug intelligence / Profile preview

FB-121

Development stage: Preclinical
Lead developer: Fountain Biopharma
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

FB-121 is a humanized monoclonal antibody biosimilar of ibalizumab (Trogarzo), currently under development by Fountain Biopharma in collaboration with Oneness Biotech for the treatment of HIV infections. As an ibalizumab-class anti-CD4 monoclonal antibody, it functions as a post-attachment entry inhibitor. FB-121 binds to the CD4 receptor on host T-cells, inducing a conformational change that prevents the HIV-1 virus from interacting with co-receptors (such as CCR5 or CXCR4) after initial attachment has occurred. This mechanism effectively blocks viral entry into the host cell. The drug is primarily designed for heavily treatment-experienced adults with multidrug-resistant HIV-1 infection.

Other names: ibalizumab biosimilar

Targets

CD4 (T lymphocyte surface antigen)

Beyond the preview

Go deeper on FB-121.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FB-121.

Explore the full profile